Thank you for highlighting the pertinent parts.

First 140 Last

Share
Profile

Follow
DumbPostAvenger

80 Posts.

40

26/04/24

17:09

Post #: 73529080
Share

Originally posted by Taurean7: ↑

In the 29/09/23 Talking Business interview Pilcher clearly indicates NEU funding the PMS Phase III trial alone to be the preferred option at that time, which he describes as Plan A. His full answer to the question on intended use of the funds received from Acadia is given below.

(6:17 time point) LG: “How will the funds be used specifically?”

JP: “Yeah, it’s a very good question, and we have a big decision to make after we get the final results from the Phase II trials in December for Phelan-McDermid Syndrome. If they’re as good as we expect then we have the option to proceed ourselves through Phase III, which we couldn’t do with Debuye because, as said, we didn’t have the money, we didn’t have the market support.”

“Probably we didn’t have the expertise in those days either, but we think we have all of these three things now. So definitely an option for us is to use that money to invest in the Phase III for the second drug, and you can get a massive uplift in value if you can do that.”

“A good example is our arrangement with Adadia. Originally at the end of Phase II we licenced them in North America and they paid us US$10 million up front. We’ve just licenced them the rest of the world for an approved product now, and they’ve paid us US$100 million up front.”

“So there is no doubt if you can take a drug to the end, you know, you retain so much more of the value.So that’s, I guess, Plan A.” (7:19 time point)

“But we are not going to commit to it until we see the data and also, you know, make sure that, from a capability point of view and a risk-reward point of view, it’s the right thing to do. And we’ll also have to talk to the FDA to make sure we’ve got them on side as we did with the first stroke(?), but we’re in a great position to contemplate all of this now.”

Expand

Thank you for highlighting the pertinent parts.

NEU Price at posting: $18.65 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 55 more messages in this thread...

First 140 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $19.82		Change 0.120(0.61%)		Mkt cap ! $2.530B

Open	High	Low	Value	Volume
$19.80	$19.82	$18.85	$6.333M	324.6K

Buyers (Bids)

No.	Vol.	Price($)
1	30	$19.70

Sellers (Offers)

Price($)	Vol.	No.
$19.83	1160	2

View Market Depth

No.	Vol.	Price($)
1	30	19.700
2	1160	19.640
1	846	19.630
1	2648	19.620
1	846	19.600

Price($)	Vol.	No.
19.830	1160	2
19.840	846	1
19.850	695	1
19.870	846	1
19.900	3846	2

Last trade - 16.10pm 06/05/2024 (20 minute delay)


Last $19.74		Change 0.120 ( 0.07 %)
Open	High	Low	Volume
$19.76	$19.80	$18.86	101075
Last updated 15.59pm 06/05/2024 ?

NEU (ASX) Chart

Thank you for highlighting the pertinent parts.

Featured News

Sold out signs go up for RIU Resources Roundup in Sydney

Mantle Minerals to kick off drilling at Mt Berghaus in WA

Tamboran is listing on the NYSE, and Wall Street is paying attention

Maiden drilling at West Arunta hints at major IOCG system for Rincon

Westpac tracks lower in profits in first half of 2024, with a 16% yoy drop amid slowing economy

Buyers (Bids)

Sellers (Offers)

Featured News

Thank you for highlighting the pertinent parts.

Featured News

Top Stories

Sold out signs go up for RIU Resources Roundup in Sydney

Mantle Minerals to kick off drilling at Mt Berghaus in WA

Tamboran is listing on the NYSE, and Wall Street is paying attention

Maiden drilling at West Arunta hints at major IOCG system for Rincon

Westpac tracks lower in profits in first half of 2024, with a 16% yoy drop amid slowing economy

Buyers (Bids)

Sellers (Offers)

Featured News